局部晚期非小细胞肺癌3DCRT联合同步化疗的临床疗效观察.docVIP

局部晚期非小细胞肺癌3DCRT联合同步化疗的临床疗效观察 　　【摘要】 目的 观察分析三维适形放射治疗（3DCRT）联合同步化疗治疗局部晚期非小细胞肺癌的临床效果。方法 68例局部晚期非小细胞肺癌患者， 根据治疗方式不同分为同步化疗组和序贯化疗组， 各34例。同步化疗组采用3DCRT联合同步化疗， 序贯化疗组采用3DCRT治疗结束后再给予化疗。对比两组疗效。结果 同步化疗组有效率为70.59%， 序贯化疗组为64.71%， 比较差异无统计学意义（P0.05）。同步化疗组2年生存率为38.2% （13/34）， 序贯化疗组为26.5% （9/34）；同步化疗组中位生存期为17.0个月， 序贯化疗组为13.0个月， 采用log-rank检验， 结果显示同步化疗组生存率优于序贯化疗组（χ2=4.83， P0.05）。结论 3DCRT联合同步化疗治疗局部晚期非小细胞肺癌效果优于序贯化疗， 两种治疗方法不良反应无差异， 患者均可耐受。 　　【关键词】 非小细胞肺癌；局部晚期；三维适形放射治疗；序贯化疗 　　DOI：10.14163/j.cnki.11-5547/r.2016.27.005 　　【Abstract】 Objective To observe and analyze clinical effect by three dimensional conformal radiation therapy （3DCRT） combined with concurrent chemotherapy in the treatment of locally advanced non-small cell lung cancer. Methods A total of 68 patients with locally advanced non-small cell lung cancer were divided by different treatment measures into concurrent chemotherapy group and sequential chemotherapy group， with 34 cases in each group. Concurrent chemotherapy group received 3DCRT combined with concurrent chemotherapy， while sequential chemotherapy group received chemotherapy after 3DCRT. Curative effects were compared between the two groups. Results There was no statistically significant difference of effective rate between concurrent chemotherapy group as 70.59% and sequential chemotherapy group as 64.71% （P0.05）. Concurrent chemotherapy group had 2-year survival rate as 38.2% （13/34）， and that in sequential chemotherapy group was 26.5% （9/34）. Median survival time was 17.0 months in concurrent chemotherapy group and 13.0 months in sequential chemotherapy group. Test by log-rank showed better survival rate in concurrent chemotherapy group than sequential chemotherapy group （χ2=4.83， P0.05）. Conclusion Combination of 3DCRT and concurrent chemotherapy provides better effect than sequential chemotherapy in treating locally advanced non-small cell lung cancer. There is no difference of adverse reactions between the two methods， and they are all tolerable in patients.